NecroX-7 reduces necrotic core formation in atherosclerotic plaques of Apoe knockout mice

Atherosclerosis

Volumn 252, Issue , 2016, Pages 166-174

  Grootaert, Mandy O J ^a   Schrijvers, Dorien M ^a   Van Spaendonk, Hanne ^a   Breynaert, Annelies ^a   Hermans, Nina ^a   Van Hoof, Viviane O ^b   Takahashi, Nozomi ^c,d   Vandenabeele, Peter ^c,d   Kim, Soon Ha ^e   De Meyer, Guido R Y ^a   Martinet, Wim ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d GHENT UNIVERSITY   (Belgium)

^e LG Chemical Ltd   (South Korea)

Author keywords

Atherosclerosis; Inflammation; Mitochondrial ROS; Necrosis; NecroX 7

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIOXIDANT; APOLIPOPROTEIN E; CASPASE 3; CHOLESTEROL; COLLAGEN TYPE 1; COLLAGENASE 3; CYCLOHEXIMIDE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; NECROX 7; REACTIVE OXYGEN METABOLITE; TERT BUTYL HYDROPEROXIDE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; COLLAGEN; HMGB1 PROTEIN, MOUSE; NECROX-7; ORGANIC COMPOUND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA ROOT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; IN VITRO STUDY; KNOCKOUT MOUSE; MACROPHAGE; MALE; MITOCHONDRION; MOUSE; NECROPTOSIS; NECROSIS; NECROTIC CORE FORMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; THORACIC AORTA; WESTERN DIET; ANIMAL; APOLIPOPROTEIN E KNOCKOUT MOUSE; ATHEROSCLEROSIS; BONE MARROW CELL; C57BL MOUSE; CYTOLOGY; INFLAMMATION; LIPID PEROXIDATION; METABOLISM;

ANIMALS; ATHEROSCLEROSIS; BONE MARROW CELLS; CHOLESTEROL, LDL; COLLAGEN; HMGB1 PROTEIN; INFLAMMATION; LIPID PEROXIDATION; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT, APOE; NECROSIS; ORGANIC CHEMICALS; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC;

EID: 84978890740     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.06.045     Document Type: Article

References (49)

1. [1] Fok, P.W., Growth of necrotic cores in atherosclerotic plaque. Math. Med. Biol. 29 (2012), 301–327.
2. [2] Virmani, R., Burke, A.P., Willerson, J., Farb, A., Narula, J., Kolodgie, F.D., The pathology of vulnerable plaque. Virmani, R., Narula, J., Leon, M., Willerson, J., (eds.) The Vulnerable Atherosclerotic Plaque: Strategies for Diagnosis and Management, 2007, Blackwell Futura, Malden, 21–36.
3. [3] Tabas, I., Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler. Thromb. Vasc. Biol. 25 (2005), 2255–2264.
4. [4] Majno, G., Joris, I., Apoptosis, oncosis, and necrosis. An overview of cell death. Am. J. Pathol. 146 (1995), 3–15.
5. [5] Seimon, T., Tabas, I., Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J. Lipid Res., 2009, 50 Suppl:S382-S387.
6. [6] Martinet, W., Schrijvers, D.M., De Meyer, G.R.Y., Necrotic cell death in atherosclerosis. Basic Res. Cardiol. 106 (2011), 749–760.
7. [7] Schrijvers, D.M., De Meyer, G.R.Y., Herman, A.G., Martinet, W., Phagocytosis in atherosclerosis: molecular mechanisms and implications for plaque progression and stability. Cardiovasc Res. 73 (2007), 470–480.
8. [8] Ball, R.Y., Stowers, E.C., Burton, J.H., Cary, N.R., Skepper, J.N., Mitchinson, M.J., Evidence that the death of macrophage foam cells contributes to the lipid core of atheroma. Atherosclerosis 114 (1995), 45–54.
9. [9] Crisby, M., Kallin, B., Thyberg, J., Zhivotovsky, B., Orrenius, S., Kostulas, V., Nilsson, J., Cell death in human atherosclerotic plaques involves both oncosis and apoptosis. Atherosclerosis 130 (1997), 17–27.
10. [10] Declercq, W., Vanden Berghe, T., Vandenabeele, P., RIP kinases at the crossroads of cell death and survival. Cell 138 (2009), 229–232.
11. [11] Zhang, D.W., Shao, J., Lin, J., Zhang, N., Lu, B.J., Lin, S.C., Dong, M.Q., Han, J., RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 325 (2009), 332–336.
12. [12] Vanden Berghe, T., Linkermann, A., Jouan-Lanhouet, S., Walczak, H., Vandenabeele, P., Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat. Rev. Mol. Cell Biol. 15 (2014), 135–147.
13. [13] Lin, J., et al. A role of RIP3-mediated macrophage necrosis in atherosclerosis development. Cell Rep. 3 (2013), 200–210.
14. [14] Harrison, C.M., Pompilius, M., Pinkerton, K.E., Ballinger, S.W., Mitochondrial oxidative stress significantly influences atherogenic risk and cytokine-induced oxidant production. Environ. Health Perspect. 119 (2011), 676–681.
15. [15] Ballinger, S.W., et al. Mitochondrial integrity and function in atherogenesis. Circulation 106 (2002), 544–549.
16. [16] Ari, E., Kaya, Y., Demir, H., Cebi, A., Alp, H.H., Bakan, E., Odabasi, D., Keskin, S., Oxidative DNA damage correlates with carotid artery atherosclerosis in hemodialysis patients. Hemodial. Int. 15 (2011), 453–459.
17. [17] Wang, Y., Wang, G.Z., Rabinovitch, P.S., Tabas, I., Macrophage mitochondrial oxidative stress promotes atherosclerosis and nuclear factor-kappaB-mediated inflammation in macrophages. Circ. Res. 114 (2014), 421–433.
18. [18] Tabas, I., Wang, Y., Emerging roles of mitochondria ROS in atherosclerotic lesions: causation or association?. J. Atheroscler. Thromb. 21 (2014), 381–390.
19. [19] Kim, H.J., et al. NecroX as a novel class of mitochondrial reactive oxygen species and ONOO scavenger. Arch. Pharm. Res. 33 (2010), 1813–1823.
20. [20] Park, J., et al. NecroX-7 prevents oxidative stress-induced cardiomyopathy by inhibition of NADPH oxidase activity in rats. Toxicol. Appl. Pharmacol. 263 (2012), 1–6.
21. [21] Chung, H.K., et al. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation. Liver Int. 35 (2015), 1341–1353.
22. [22] Im, K.I., Kim, N., Lim, J.Y., Nam, Y.S., Lee, E.S., Kim, E.J., Kim, H.J., Kim, S.H., Cho, S.G., The free radical scavenger NecroX-7 attenuates acute graft-versus-host disease via reciprocal regulation of Th1/Regulatory T cells and inhibition of HMGB1 release. J. Immunol. 194 (2015), 5223–5232.
23. [23] Cho, H.J., Hwang, I.C., Kim, J.Y., Lee, H.S., Lee, J., Park, J., et al. Therapeutic potential of a novel necrosis inhibitor in myocardial ischemia-reperfusion injury. Circ. Res., 117, 2015, A263 (Abstract).
24. [24] Hermans, N., Cos, P., Berghe, D.V., Vlietinck, A.J., de, B.T., Method development and validation for monitoring in vivo oxidative stress: evaluation of lipid peroxidation and fat-soluble vitamin status by HPLC in rat plasma. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 822 (2005), 33–39.
25. [25] Newton, K., Sun, X., Dixit, V.M., Kinase RIP3 is dispensable for normal NF-kappa Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. Mol. Cell Biol. 24 (2004), 1464–1469.
26. [26] Seimon, T.A., Wang, Y., Han, S., Senokuchi, T., Schrijvers, D.M., Kuriakose, G., Tall, A.R., Tabas, I.A., Macrophage deficiency of p38alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. J. Clin. Invest. 119 (2009), 886–898.
27. [27] Junqueira, L.C., Cossermelli, W., Brentani, R., Differential staining of collagens type I, II and III by Sirius Red and polarization microscopy. Arch. Histol. Jpn. 41 (1978), 267–274.
28. [28] Hellemans, J., Mortier, G., De, P.A., Speleman, F., Vandesompele, J., qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol., 8, 2007, R19.
29. [29] Thu, V.T., et al. NecroX-5 prevents hypoxia/reoxygenation injury by inhibiting the mitochondrial calcium uniporter. Cardiovasc Res. 94 (2012), 342–350.
30. [30] Choi, J.M., Park, K.M., Kim, S.H., Hwang, D.W., Chon, S.H., Lee, J.H., Lee, S.Y., Lee, Y.J., Effect of necrosis modulator necrox-7 on hepatic ischemia-reperfusion injury in beagle dogs. Transpl. Proc. 42 (2010), 3414–3421.
31. [31] Park, J.H., et al. An indole derivative protects against acetaminophen-induced liver injury by directly binding to N-acetyl-p-benzoquinone imine in mice. Antioxid. Redox Signal 18 (2013), 1713–1722.
32. [32] Kim, S.R., Kim, D.I., Kim, S.H., Lee, H., Lee, K.S., Cho, S.H., Lee, Y.C., NLRP3 inflammasome activation by mitochondrial ROS in bronchial epithelial cells is required for allergic inflammation. Cell Death Dis., 5, 2014, e1498.
33. [33] Shin, E., Lee, Y.C., Kim, S.R., Kim, S.H., Park, J., Drug signature-based finding of additional clinical use of LC28-0126 for neutrophilic bronchial asthma. Sci. Rep., 5, 2015, 17784.
34. [34] Li, X., Kwon, O., Kim, D.Y., Taketomi, Y., Murakami, M., Chang, H.W., NecroX-5 suppresses IgE/Ag-stimulated anaphylaxis and mast cell activation by regulating the SHP-1-Syk signaling module. Allergy 71 (2016), 198–209.
35. [35] Jin, S.A., et al. Beneficial effects of necrosis modulator, indole derivative NecroX-7, on renal ischemia-reperfusion injury in rats. Transpl. Proc. 48 (2016), 199–204.
36. [36] Falk, E., Nakano, M., Bentzon, J.F., Finn, A.V., Virmani, R., Update on acute coronary syndromes: the pathologists’ view. Eur. Heart J. 34 (2013), 719–728.
37. [37] Scaffidi, P., Misteli, T., Bianchi, M.E., Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418 (2002), 191–195.
38. [38] Andersson, U., et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 192 (2000), 565–570.
39. [39] Erlandsson, H.H., Andersson, U., Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur. J. Immunol. 34 (2004), 1503–1512.
40. [40] Kalinina, N., Agrotis, A., Antropova, Y., DiVitto, G., Kanellakis, P., Kostolias, G., Ilyinskaya, O., Tararak, E., Bobik, A., Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler. Thromb. Vasc. Biol. 24 (2004), 2320–2325.
41. [41] Gardella, S., Andrei, C., Ferrera, D., Lotti, L.V., Torrisi, M.R., Bianchi, M.E., Rubartelli, A., The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3 (2002), 995–1001.
42. [42] Li, X., Fang, P., Mai, J., Choi, E.T., Wang, H., Yang, X.F., Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers. J. Hematol. Oncol., 6, 2013, 19.
43. [43] de Souza-Pinto, N.C., Eide, L., Hogue, B.A., Thybo, T., Stevnsner, T., Seeberg, E., Klungland, A., Bohr, V.A., Repair of 8-oxodeoxyguanosine lesions in mitochondrial dna depends on the oxoguanine dna glycosylase (OGG1) gene and 8-oxoguanine accumulates in the mitochondrial dna of OGG1-defective mice. Cancer Res. 61 (2001), 5378–5381.
44. [44] Madamanchi, N.R., Vendrov, A., Runge, M.S., Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol. 25 (2005), 29–38.
45. [45] Cherubini, A., Vigna, G.B., Zuliani, G., Ruggiero, C., Senin, U., Fellin, R., Role of antioxidants in atherosclerosis: epidemiological and clinical update. Curr. Pharm. Des. 11 (2005), 2017–2032.
46. [46] Otani, H., Site-specific antioxidative therapy for prevention of atherosclerosis and cardiovascular disease. Oxid. Med. Cell Longev., 2013, 2013, 796891.
47. [47] Smith, R.A., Murphy, M.P., Mitochondria-targeted antioxidants as therapies. Discov. Med. 11 (2011), 106–114.
48. [48] Upston, J.M., Kritharides, L., Stocker, R., The role of vitamin E in atherosclerosis. Prog. Lipid Res. 42 (2003), 405–422.
49. −/− mice. Free Radic. Biol. Med. 52 (2012), 841–849.